Salbutamol: common myths about effects and safety

Two opposite legends have formed around salbutamol. Some consider it a hidden doping, thanks to which athletes with asthma win medals. Others - a harmless remedy that can be taken as you like, because it is "given even to children." The editors have collected the most common claims and verified them against clinical studies and meta-analyses.

Myth 1: "The inhaler gives asthmatics an advantage"

Among elite athletes, the proportion of people with asthma or exercise-induced bronchospasm is higher than in the general population. This is especially noticeable in cross-country skiing, swimming, cycling and biathlon. This raises the suspicion that perhaps the diagnosis of "asthma" is just a way to get a legal stimulant.

However, the explanation for the high prevalence is mostly physiological. Prolonged breathing in large volumes of cold, dry air or air with chlorinated compounds in the pool damages the epithelium of the respiratory tract and provokes their inflammation. The consensus of the International Olympic Committee in 2008 recognized asthma as the most common chronic disease among Olympians, associating it precisely with training conditions.

With regard to performance, a systematic review and meta-analysis by Pluim et al (2011) found no improvement in endurance, strength or anaerobic performance in healthy athletes with therapeutic doses of inhaled beta-2 agonists. A similar conclusion was made by Kindermann (2007): inhaled doses have no proven ergogenic potential in athletes without asthma.

For an athlete with asthma, the inhaler does not provide any benefits, but only restores the normal state of the respiratory tract. Without it, a person would train and compete in worse conditions than rivals.

At the same time, a meta-analysis by Riiser et al. (2020) showed: when administered systemically and in doses higher than therapeutic, beta-2-agonists can improve sprinting and strength performance. So the myth has a rational grain — but it's about the abuse itself, not the treatment.

Myth 2: "Salbutamol is a lightweight clenbuterol for drying"

On forums, salbutamol tablets are sometimes advertised as a "milder and safer" alternative to clenbuterol for fat loss. Both substances are indeed beta-2 agonists, but their pharmacokinetics differ dramatically.

Data on the effect of salbutamol on fat mass in humans are limited. Studies by the Hostrup group have shown that systemic beta-2 agonists can increase lipolysis and energy expenditure, and long-term high oral doses can affect body composition. However, these works had research purposes, were carried out under medical supervision and are not grounds for independent use.

The main thing: the "softness" of salbutamol disappears with the transition from an inhaler to tablets. Tachycardia, tremors, insomnia, muscle spasms due to potassium loss and the risk of arrhythmias are direct consequences of systemic beta stimulation. In a person without asthma, such a reception has no medical justification and, moreover, is a violation of anti-doping rules.

Tolerance must also be taken into account: with long-term stimulation, beta-2 receptors lose sensitivity (desensitization). Due to this, the effect on metabolism weakens over time, and side effects remain.

Myth 3: "The drug is safe because it is given to children"

Salbutamol is really widely used in pediatrics, and it is one of the most studied drugs in pulmonology. But the safety of any medicine is determined by the context: the indication, the dose, the method of administration and the patient's condition.

A child with asthma is prescribed inhalation through a spacer in a dose designed to relieve bronchospasm. This is a completely different situation than an adult athlete who swallows pills against the backdrop of a caloric deficit, dehydration, caffeine and intense training.

The instructions for salbutamol describe serious, albeit rare, side effects: myocardial ischemia, arrhythmias, severe hypokalemia, lactic acidosis at high doses, allergic reactions, and paradoxical bronchospasm. The risk of these complications increases with the systemic dose.

The advice "you can, because they give it to children" is similar to the logic "paracetamol is safe, so you can drink a pack." Medical safety is always tied to the instructions, not to the name of the substance.

Myth 4: "The more frequent the inhalation, the better the control of asthma"

This myth is widespread not only among athletes, but also among patients in general. Salbutamol relieves symptoms quickly, so regular inhalations seem to "keep asthma under control." In fact, it does not affect the inflammation of the respiratory tract - the basis of the disease.

Epidemiological data link the overuse of short-acting beta-agonists with an increased risk of severe asthma exacerbations and death. That is why, since 2019, the Global Initiative for Asthma (GINA) no longer recommends treating adults and adolescents with only short-acting beta-agonists without an inhaled corticosteroid.

If an athlete needs an inhaler every day or several times before each workout, this is a signal to consult a pulmonologist or allergist for a review of basic therapy, rather than increasing the number of inhalations.

In addition, frequent use of beta-agonists can reduce the sensitivity of receptors, due to which the protective effect before exercise gradually weakens. This is another reason not to rely solely on a "rescue" inhaler.

Myths about doping control

There are also several persistent errors surrounding the anti-doping status of salbutamol. Let's analyze the most common ones briefly.

• "The inhaler requires a TUE." No, inhaled salbutamol within the limits of 1600 mcg per day and 600 mcg in 8 hours is permitted without a therapeutic use permit. A TUE is required for higher doses or systemic forms.
• "Froome disqualified for salbutamol". No, in 2018 the UCI closed the case and WADA agreed that no violation had been proven.
• "If you stick to the dose, the sample will always be clean." Not guaranteed: Dehydration and individual metabolism may increase urinary concentrations. Therefore, it is important not to approach the upper limit unnecessarily.
• "Cough syrup doesn't count." Counts: oral forms of beta-2-agonists are prohibited regardless of dose.

A common feature of these myths is ignoring the difference between inhalation therapy and systemic use. It is this difference that is embedded in the WADA rules, and it is this that determines both safety and legality.

Another common mistake concerns "foreign" inhalers. The tool borrowed from a teammate may contain a different substance or combination with a corticosteroid, and the dose per inhalation will differ. The athlete is responsible for everything that enters his body.

Finally, some believe that WADA is "persecuting asthmatics". In fact, the rules for beta-2 agonists have been gradually relaxed: the TUE requirement for inhaled salbutamol within the limit was abolished as early as 2010.

Editorial conclusion

Inhaled salbutamol in therapeutic doses does not improve the sports performance of healthy people, and for people with asthma it only compensates for the disease. Ergogenic potential appears with systemic administration and high doses — and that's when the risks increase.

Salbutamol tablets are not "light clenbuterol" and have no medical basis for fat loss. The safety of the drug in pediatrics does not transfer to non-medical regimens.

Frequent use of a rescue inhaler is a sign of poor asthma control that requires a review of treatment rather than an increase in the number of inhalations.

Read more about these topics in our articles Salbutamol Status with WADA, Salbutamol Contraindications and Clenbuterol Myths Review.

References

1. Pluim BM, de Hon O, Staal JB, et al. β2-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials. Sports Med. 2011;41(1):39–57.
2. Kindermann W. Do inhaled β2-agonists have an ergogenic potential in non-asthmatic competitive athletes? Sports Med. 2007;37(2):95–102.
3. Riiser A, Stensrud T, Stang J, Andersen LB. Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs. Br J Sports Med. 2020;54(22):1351–1359.
4. Fitch KD, Sue-Chu M, Anderson SD, et al. Asthma and the elite athlete: summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22–24, 2008. J Allergy Clin Immunol. 2008;122(2):254–260.
5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA; 2024.
6. Hostrup M, Jacobson GA, Jessen S, Lemminger AK. Anabolic and lipolytic actions of beta2-agonists in humans and antidoping challenges. Drug Test Anal. 2020;12(5):597–609.
7. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. WADA; current edition.